Drug intelligence / Profile preview

glucose sensing insulin receptor agonist therapeutic

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules

Overview

Glucose sensing insulin receptor agonist therapeutic is a novel antihyperglycemic agent under development by Eli Lilly and Company. It acts as an agonist of the insulin receptor with a mechanism designed to sense and respond to glucose levels, potentially offering improved glycemic control for patients with diabetes mellitus and obesity. This drug represents a new molecular entity in the class of antihyperglycemics and obesity therapies. As of early 2024, it is in Phase I clinical trials for both diabetes mellitus and obesity[1].

Other names: GS Insulin Receptor Agonistglucose sensing insulin receptor agonist therapeutic

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on glucose sensing insulin receptor agonist therapeutic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glucose sensing insulin receptor agonist therapeutic.

Explore the full profile